Stock FGEN FIBROGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company FibroGen, Inc.

Equities

FGEN

US31572Q8087

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
1.02 USD +3.63% Intraday chart for FibroGen, Inc. -12.82% +15.09%
Apr. 15 Faron Pharmaceuticals reappoints former finance chief on interim basis AN
Apr. 03 Top Midday Decliners MT

Business Summary

FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.

Number of employees: 486

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Therapeutics
100.0 %
141 100.0 % 148 100.0 % +4.99%

Sales per region

USD in Million2022Weight2023Weight Delta
China
74.0 %
85 60.1 % 109 74.0 % +29.24%
Japan
10.7 %
10 6.9 % 16 10.7 % +62.51%
United States
8.8 %
13 8.9 % 13 8.8 % +3.53%
Europe
6.5 %
34 24.0 % 10 6.5 % -71.77%

Managers

Managers TitleAgeSince
Thane Wettig CEO
 Chief Executive Officer 59 20-06-21
Juan Graham DFI
 Director of Finance/CFO 48 21-09-06
James Schoeneck CHM
 Chairman 66 10-03-31
Rahul Rajan Kaushik CTO
 Chief Tech/Sci/R&D Officer - -
John Hunter CTO
 Chief Tech/Sci/R&D Officer 61 21-07-11
Elias Kouchakji CTO
 Chief Tech/Sci/R&D Officer 67 13-12-31
Meichiel Keenan IRO
 Public Communications Contact - 04-04-30
David DeLucia IRC
 Investor Relations Contact - -
Tricia Stewart HRO
 Human Resources Officer - 21-04-30
Christine Chung L. PRN
 Corporate Officer/Principal 56 06-12-31

Members of the board

Members of the board TitleAgeSince
Jeffrey Edwards BRD
 Director/Board Member 64 15-10-27
Jeffrey Henderson BRD
 Director/Board Member 59 15-08-05
May Kin Ho BRD
 Director/Board Member 71 18-12-05
Benjamin Cravatt BRD
 Director/Board Member 54 20-08-04
Gerald Lema BRD
 Director/Board Member 63 17-09-18
James Schoeneck CHM
 Chairman 66 10-03-31
Suzanne Blaug BRD
 Director/Board Member 66 19-06-04
Aoife Brennan BRD
 Director/Board Member 48 20-08-04
Thane Wettig CEO
 Chief Executive Officer 59 20-06-21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 98,771,247 92,481,524 ( 93.63 %) 0 93.63 %

Shareholders

NameEquities%Valuation
PRIMECAP Management Co.
14.65 %
14,471,928 14.65 % 34 M $
Armistice Capital LLC
9.885 %
9,764,000 9.885 % 23 M $
Vanguard Fiduciary Trust Co.
7.132 %
7,044,149 7.132 % 17 M $
BlackRock Advisors LLC
7.029 %
6,943,045 7.029 % 16 M $
ASTELLAS PHARMA INC.
5.030 %
4,968,367 5.030 % 12 M $
Jacobs Levy Equity Management, Inc.
2.520 %
2,489,506 2.520 % 6 M $
Acadian Asset Management LLC
2.500 %
2,468,928 2.500 % 6 M $
Citadel Securities GP LLC
2.420 %
2,390,681 2.420 % 6 M $
Assenagon Asset Management SA
2.255 %
2,226,857 2.255 % 5 M $
Two Sigma Investments LP
2.127 %
2,101,283 2.127 % 5 M $

Company contact information

FibroGen, Inc.

409 Illinois Street

94158-2509, San Francisco

+415 978 1200

http://www.fibrogen.com
address FibroGen, Inc.(FGEN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for FibroGen, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
3
Last Close Price
0.9843 USD
Average target price
1.75 USD
Spread / Average Target
+77.79%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
FIBROGEN, INC. Stock FibroGen, Inc.
+15.09% 97.22M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.12% 43.84B
MODERNA, INC. Stock Moderna, Inc.
+6.77% 41.68B
LONZA GROUP AG Stock Lonza Group AG
+45.26% 41.25B
CELLTRION, INC. Stock Celltrion, Inc.
-11.96% 27.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.01% 25.53B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.92% 18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.63% 12.29B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.16% 12.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.30% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. FGEN Stock
  4. Company FibroGen, Inc.